TNFSF10 and non-small cell lung carcinoma: Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) was developed as an anticancer therapy but failed as a late-stage treatment due to TRAIL resistance in many NSCLC tumors.